search
Back to results

Dietary Management of Gestational Diabetes in Obese Pregnant Women (eMOM)

Primary Purpose

Diabetes, Gestational, Dietary Modification, Tissue Glucose

Status
Terminated
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
Carbohydrate restricted diet
Plant-protein based diet
Sponsored by
Helsinki University Central Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes, Gestational

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Early gestational diabetes (pregnancy weeks 10-15)
  • BMI ≥ 30 kg/m2
  • Pregnancy confirmed with ultrasound screening

Exclusion Criteria:

  • Multiparous pregnancy
  • Food allergies or restrictions (other than lactose intolerance)
  • Mother's or father's ethnic background other than Caucasian
  • Type 1 or type 2 diabetes
  • Medication which affects glucose metabolism
  • Cholesterol medication
  • Drug or alcohol abuse
  • Psychiatric illness which affects participation in study
  • Factors hampering communication (e.g. lack of Finnish skills)

Sites / Locations

  • Helsinki university central hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Carbohydrate restricted diet

Plant-protein based diet

Arm Description

Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.

Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.

Outcomes

Primary Outcome Measures

Mother: The percentage of time spent within the gestational diabetes glucose target range (<7,8 mmol/l)
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Mother: The percentage of time spent within the gestational diabetes glucose target range (<7,8 mmol/l)
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Child: Neonatal body fat%
Neonatal body fat%; Measured with PEA POD Cosmed® Infant Body Composition Assessment system

Secondary Outcome Measures

Mother: The percentage of time spent within the gestational diabetes glucose target range (<7,8 mmol/l) in cross-over phase
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Mother: Glycaemic variability in crossover phase
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Mother: Glycaemic variability
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Mother: Glycaemic variability
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Percentage of participants on GDM medication

Full Information

First Posted
April 3, 2018
Last Updated
October 22, 2019
Sponsor
Helsinki University Central Hospital
Collaborators
University of Helsinki, Aalto University, Finnish Institute for Health and Welfare, City of Helsinki, UKK Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT03542071
Brief Title
Dietary Management of Gestational Diabetes in Obese Pregnant Women
Acronym
eMOM
Official Title
Effects of a Standardized Dietary Intake on Metabolic Outcomes in Obese Pregnant Women With Gestational Diabetes and on Offspring Body Composition
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Terminated
Why Stopped
The study protocol was changed because of too few eligible participants. A registration with revised protocol can be found by ClinicalTrials.gov ID NCT03681054.
Study Start Date
July 20, 2018 (Actual)
Primary Completion Date
March 23, 2019 (Actual)
Study Completion Date
March 23, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Helsinki University Central Hospital
Collaborators
University of Helsinki, Aalto University, Finnish Institute for Health and Welfare, City of Helsinki, UKK Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
eMOM is a randomized, controlled trial to compare the effects of two different dietary interventions during pregnancy. The comparison is based on tissue glucose content (using continuous glucose monitoring system) in pregnant women and on neonate body composition. The recruited women (n=50) have early gestational diabetes mellitus (diagnosed before gestational weeks 13), are obese (BMI >30 kg/m²) and of Caucasian origin. Of the study diets, one is moderately carbohydrate restricted and the other one is high on plant-based protein with an emphasis on healthy Nordic foods. The study has three two-week study periods that are carried out on approximately gestational weeks 13-14 (period I), 24-25 (period II) and 34-35 (period III). Continuous glucose monitoring and other measurements (accelerometer, 3-day food record, gut microbiota, serum lipids, metabolomics, epigenetics etc.) are done during these study periods. At the beginning of the study, before study period I, the participants are randomized to either one of the intervention diets. The first study period consists of a crossover phase in which the participants receive three days' worth of food according to one of the intervention diets (according to the randomization) after which there is a three-day wash-out period. After the wash-out period, the participants receive three days' worth of food according to the other diet. After the first study period, a nutritionist advises the lastly followed intervention diet to the participant and the diet is followed until delivery. To ensure the diet is followed, the participant gets at least five personal counselling sessions, mobile reminders, recipes and food items. After delivery, the infant's body composition, epigenetic markers of cord blood and placenta, gut microbiome and urine metabolomics are measured.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Gestational, Dietary Modification, Tissue Glucose, Body Composition, Birth Weight

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Carbohydrate restricted diet
Arm Type
Experimental
Arm Description
Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
Arm Title
Plant-protein based diet
Arm Type
Experimental
Arm Description
Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
Intervention Type
Other
Intervention Name(s)
Carbohydrate restricted diet
Intervention Description
The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
Intervention Type
Other
Intervention Name(s)
Plant-protein based diet
Intervention Description
The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
Primary Outcome Measure Information:
Title
Mother: The percentage of time spent within the gestational diabetes glucose target range (<7,8 mmol/l)
Description
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Time Frame
Study period II: during a 14 day period within gestational weeks 23-26
Title
Mother: The percentage of time spent within the gestational diabetes glucose target range (<7,8 mmol/l)
Description
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Time Frame
Study period III: during a 14 day period within gestational weeks 33-36
Title
Child: Neonatal body fat%
Description
Neonatal body fat%; Measured with PEA POD Cosmed® Infant Body Composition Assessment system
Time Frame
one measure within 0-2 days after birth of the child
Secondary Outcome Measure Information:
Title
Mother: The percentage of time spent within the gestational diabetes glucose target range (<7,8 mmol/l) in cross-over phase
Description
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Time Frame
Study period I: during a 3 day intervention-diet period within gestational weeks 12-15
Title
Mother: Glycaemic variability in crossover phase
Description
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Time Frame
Study period I: during a 3 day intervention-diet period within gestational weeks 12-15
Title
Mother: Glycaemic variability
Description
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Time Frame
Study period II: during a 14 day period within gestational weeks 23-26
Title
Mother: Glycaemic variability
Description
Measured with FreeStyle®Libre, Continuous Glucose Monitoring system
Time Frame
Study period III: during a 14 day period within gestational weeks 33-36
Title
Percentage of participants on GDM medication
Time Frame
Up to 42 gestational weeks

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Early gestational diabetes (pregnancy weeks 10-15) BMI ≥ 30 kg/m2 Pregnancy confirmed with ultrasound screening Exclusion Criteria: Multiparous pregnancy Food allergies or restrictions (other than lactose intolerance) Mother's or father's ethnic background other than Caucasian Type 1 or type 2 diabetes Medication which affects glucose metabolism Cholesterol medication Drug or alcohol abuse Psychiatric illness which affects participation in study Factors hampering communication (e.g. lack of Finnish skills)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seppo Heinonen, prof
Organizational Affiliation
Head of department of obst et gyn / Helsinki Unversity Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Helsinki university central hospital
City
Helsinki
Country
Finland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dietary Management of Gestational Diabetes in Obese Pregnant Women

We'll reach out to this number within 24 hrs